AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tonyt who wrote (393)	8/16/1997 11:13:00 AM
From: David Bogdanoff	of 2173

Ultimately, what counts is what indication the FDA approves the product for and how compelling its use is for the target population. The clinical trial program leaves some important questions up in the air. It is of concern that they are looking at subgroups. These press releases have to be read very carefully because the are crafted by experts to give the most positive spin and de-emphasize the negative, without actually dissembling. I hoped to see more compelling results than what was described in the press release; we do not have any breakthrough here, imo. We are looking at a marginal increase that just might be good enough to result in substantial sales for this large market. David

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next